Since the start of the coronavirus pandemic, the FAMHP teams have been working relentlessly and have devoted a lot of resources to monitoring medical devices delivered to Belgium and imported medicinal products.
Since the start of the coronavirus pandemic, the FAMHP teams have been working relentlessly and have devoted a lot of resources to support healthcare professionals and to ensure the quality and safety of medicinal products and medical devices used to treat COVID-19 patients. But the efforts do not stop. The FAMHP is now doing everything to prevent any shortage of medicinal products or medical devices in the event of a second wave of COVID-19.
Since the start of the coronavirus pandemic, the FAMHP teams have been working relentlessly to support hospitals facing difficulties with supplies of medicinal products used in the treatment of COVID-19 patients. In addition, given the specific context of use of these medicinal products, the FAMHP has ensured close monitoring of adverse reactions.
Early October 2019, the European Medicines Agency (EMA), together with the European medicines authorities, including the FAMHP, asked all marketing authorisation holders to perform a risk assessment on the presence of nitrosamines as a precaution. The result of this risk assessments (step 1) must be reported via the particular web form before 1 October 2020. Another particular web form is available for submitting the results of the confirmatory tests (step 2).
The new BelVet-SAC report which contains an overview of the use of antibiotics in veterinary medicine is available. The 2019 results confirm the trends of previous years with consumption down 7.8% for mg of active substance/kg of biomass compared to last year. Compared to the 2011 reference year, the use of antibiotics in veterinary medicine has decreased by 40.3%.
Since the start of the coronavirus pandemic, the FAMHP teams have been working relentlessly to support hospitals and pharmacies facing difficulties in securing supplies of medicinal products. Here is an overview of the measures put in place by the FAMHP to guarantee stocks of medicinal products in Belgium.